<DOC>
	<DOCNO>NCT01847118</DOCNO>
	<brief_summary>This study ass safety , tolerability pharmacokinetics single dose multiple dos humanize anti-VEGF monoclonal antibody ( Sevacizumab ) patient advance metastatic solid tumor . The secondary objective explore preliminary anti-tumor effect .</brief_summary>
	<brief_title>A Phase Ia , Dose Escalation Study Humanized Anti-VEGF Monoclonal Antibody ( Sevacizumab ) Injection Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically cytologically confirm advanced metastatic malignant solid tumor ; Patients fail standard antitumor therapy n't standard regimen ; At least one measurable lesion ; At least 4 week last chemotherapy , 6 week mitomycin , nitrosourea treatment . If patient receive antitumor biological product , least four t1/2 washout period need ; Toxicity previous treatment restore ≤ grade 1 ( NCI CTC4.0 ) ; ECOG performance status 01 ; Life expectancy ≥ 3 month ; Adequate hematologic function : ANC ≥ 1.5 × 10^9 /L , HB ≥ 90 g /L ( blood transfusion allow ) , PLT ≥ 100 × 10^9 /L ; Adequate hepatic function : ALT ≤ 2.5 × ULN , AST ≤ 2.5 × ULN , TBIL ≤ 1.5 × ULN ( patient liver metastasis ALT ≤ 5 × ULN , AST ≤ 5 × ULN , TBIL ≤ 3 × ULN ) ; Adequate renal function : creatinine ≤ 1 × ULN ; Coagulation function : INR ≤ 1.5 × ULN , APTT ≤ 1.5 × ULN ; Patients childbearing potential ( male female ) must agree use reliable method contraception least 12 week last dose . HCV , TP HIV antibody positive ; Previously receive antiVEGF protein drug , bevacizumab ; Histologically proven squamous cell lung cancer squamous cell carcinoma head neck ; Active hepatitis B infection ; Evidence serious infection ; Symptomatic brain metastasis ; Patients proteinuria screen ( urine protein ≥ 1+ ) ; History abdominal fistula , gastrointestinal perforation , abdominal abscess within 6 month prior enrollment ; Serious nonhealing wound , ulcer fracture ; Major surgery ( exclude biopsy ) significant trauma within 4 week prior enrollment ; Active bleeding within 3 month prior enrollment ; Bleeding diathesis coagulation disorder ; History arterial venous thrombosis ; History myocardial infarction stroke within 6 month prior enrollment ; Unstable angina , congestive heart failure , New York Heart Association ( NYHA ) class II heart failure , uncontrollable arrhythmia , uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) ; Pregnant lactate woman ; Known allergy excipient study drug ; Patients alcohol drug dependence ; Participation clinical trial within 4 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>